SCHEMBL22604802

SCHEMBL22604802

Cc1cc(C)c(CNC(=O)c2cc(-c3ccc(N4CCN(CCNC(=O)CCCC5CC6CCCC(C5)C6)CC4)nc3)cc3c2cnn3C(C)C)c(=O)[nH]1

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 5/20 0.78
▸ HDAC6 Q9UBN7 15/20 0.75
▸ HDAC1 Q13547 11/20 0.74
▸ EZH1 Q92800 2/20 0.70
▸ EED O75530 1/20 0.70
▸ RBBP4 Q09028 1/20 0.70
▸ SUZ12 Q15022 1/20 0.70
▸ RBBP7 Q16576 1/20 0.70
▸ AEBP2 Q6ZN18 1/20 0.70
▸ HDAC4 P56524 1/20 0.64
▸ HDAC7 Q8WUI4 1/20 0.64
▸ HDAC2 Q92769 1/20 0.64
▸ HDAC10 Q969S8 1/20 0.64
▸ HDAC11 Q96DB2 1/20 0.64
▸ HDAC8 Q9BY41 1/20 0.64
▸ HDAC9 Q9UKV0 1/20 0.64
▸ HDAC5 Q9UQL6 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21285119 0.96 EZH2 (0.74) EZH2HDAC6HDAC1EZH1EED
SCHEMBL21285066 0.94 EZH1 (0.72) EZH2HDAC6HDAC1EZH1EED
SCHEMBL21285078 0.93 EZH2 (0.75) EZH2HDAC6HDAC1EZH1EED
SCHEMBL22604800 0.89 EZH2 (0.78) EZH2HDAC6HDAC1EZH1EED
SCHEMBL22604751 0.89 EZH2 (0.70) EZH2HDAC6HDAC1EZH1EED
SCHEMBL21271670 0.89 EZH2 (0.89) EZH2HDAC6HDAC1EZH1EED
SCHEMBL30123033 0.89 EZH2 (0.89) EZH2HDAC6HDAC1EZH1EED
SCHEMBL21271642 0.89 HDAC6 (0.80) EZH2HDAC6HDAC1EZH1EED
SCHEMBL30123015 0.89 HDAC6 (0.80) EZH2HDAC6HDAC1EZH1EED
SCHEMBL21271676 0.88 EZH2 (0.81) EZH2HDAC6HDAC1EZH1EED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230114294-A1 COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2023-04-13 — — US disclosed
US-20200338070-A1 COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER ICAHN SCHOOL MED MOUNT SINAI (US) 2020-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200338070-A1 COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER EZH2, EZH1, EED EZH2 1/4885HDAC6 138/4885HDAC1 73/4885
US-20230114294-A1 COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER EZH2, EZH1, EED EZH2 1/4885HDAC6 138/4885HDAC1 73/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback